Table 1

Main characteristics of patients (n=152)

Characteristicn (%)
Median age (range)62 (30–92)
Gender
Female58 (38)
Male94 (62)
Performance status
ECOG 0 & 1127 (84)
ECOG ≥225 (16)
Stage IV cancer152 (100)
Immunotherapy
Anti PD1/PD-L1 monotherapy137 (90)
Anti PD1/PD-L1 in combination with another ICI15 (10)
Histology
Adenocarcinoma149 (98)
Other3 (2)
PD-L1 expression
High (≥1%)64 (42)
Low (<1%)85 (56)
Not evaluable3 (2)
MSI status
MSS62 (41)
MSI-high2 (1)
Unknown88 (58)
Previous lines of treatment
≤193 (61)
>120 (13)
Missing39 (26)
Best response to ICI (RECIST V.1.1)
OR51 (33)
SD36 (24)
PD58 (38)
Unknown7 (5)
  • ECOG, The Easter Cooperative Oncology Group; ICI, immune checkpoint inhibitor; MSI, microsatellite instability; MSS, microsatellite stable; OR, objective response; PD1, programmed cell death 1; PD, progression disease; PD-L1, programmed death-ligand 1; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.